Sectors

SBFM
Sunshine Biopharma, Inc.
0.90
1 x 1.03
2 x 1.33
bid
ask
+
0.06
6.98%
2 @ 07:31 PM
0.88 -0.02 (2.23%)
Ytd-92.68%
1y-93.88%
0.82
day range
0.90
0.84
52 week range
22.00
Open0.82Prev Close0.84Low0.82High0.90Mkt Cap3.49M
Vol157.77KAvg Vol530.25KEPS-9.16P/EN/AForward P/E0.02
Beta-1.04Short Ratio0.39Inst. Own1.84%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1850-d Avg1.34200-d Avg7.481yr Est300.00
Earning
DateForEstimateReportedSurprisesurprise %
2024-11-052024-090-0.94N/AN/A
2024-08-162024-060-9.94N/AN/A
2024-05-202024-030-40N/AN/A
2024-03-282023-120-100N/AN/A
2023-11-132023-090-80N/AN/A
2023-08-112023-060-40N/AN/A
Upgrade / Downgrade
DateFirmActionFromTo
2024-12-05Aegis CapitalUpgradeBuyBuy
2023-08-07Aegis CapitalUpgradeBuy
Profile
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is based in Fort Lauderdale, Florida.
Insider Holder
DateNameRelationQuantityDescription
2021-01-05MERZOUKI ABDERRAZZAKChief Operating Officer23.34MStock Award(Grant)
2022-11-29SEBAALY CAMILLEChief Financial Officer174.47KPurchase
2021-01-05SLILATY STEVE NChief Executive Officer23.34MStock Award(Grant)
Institution Ownership
Report DateOrganizationPositionValuePercentage
2024-09-29Bank of America Corporation34.48K103.44K1.72%
2024-09-29Nordwand Advisors, LLC 500.001.50K0.03%
2024-09-29Rise Advisors, LLC 1.003.000.00%
2024-09-29Farther Finance Advisors, Llc1.003.000.00%
2024-09-29National Bank of Canada/FI7.0021.000.00%
2024-09-29Federation Des Caisses Desjardins Du Quebec1.003.000.00%
Fund Ownership
Report DateOrganizationPositionValuePercentage
2024-08-30Fidelity NASDAQ Composite Index Fund11.0033.000.00%
Split
SplitDate
1 : 102026-06-01
1 : 202024-08-08
1 : 1002024-04-17
1 : 2002022-02-09
1 : 202020-04-06
1 : 202019-02-01